Candel Therapeutics Files 8-K
Ticker: CADL · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1841387
Sentiment: neutral
Topics: 8-K, financial-reporting, corporate-update
TL;DR
Candel Therapeutics filed an 8-K on 10/28/24 covering financial statements and other events.
AI Summary
Candel Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting on financial statements and exhibits, along with other events and a Regulation FD disclosure. The company, incorporated in Delaware, is involved in biological products and is headquartered in Needham, MA.
Why It Matters
This filing provides updates on Candel Therapeutics' corporate activities and financial reporting, which are important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant events or financial updates without immediate, high-impact news.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- October 28, 2024 (date) — Date of Report
- Needham, MA (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing for Candel Therapeutics?
The primary purpose is to report on financial statements and exhibits, along with other events and a Regulation FD disclosure, as of October 28, 2024.
When was Candel Therapeutics, Inc. incorporated?
Candel Therapeutics, Inc. was incorporated in Delaware.
What is the business address of Candel Therapeutics?
The business address is 117 Kendrick St., Suite 450, Needham, MA 02494.
What is the SIC code for Candel Therapeutics?
The Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the fiscal year end for Candel Therapeutics?
The fiscal year end for Candel Therapeutics is December 31.
Filing Stats: 707 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-10-28 08:30:08
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq
Filing Documents
- cadl-20241028.htm (8-K) — 48KB
- cadl-ex99_1.htm (EX-99.1) — 31KB
- img160460863_0.jpg (GRAPHIC) — 32KB
- 0000950170-24-117578.txt ( ) — 250KB
- cadl-20241028.xsd (EX-101.SCH) — 27KB
- cadl-20241028_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 28, 2024, Candel Therapeutics, Inc. (the "Company") issued a press release reporting safety and tolerability data arising from the multiple injection cohort of the ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma (rHGG) and describing early clinical data and biomarker analysis from the first six patients enrolled in this cohort. The Company presented the data at the 2024 International Oncolytic Virotherapy Conference Annual Meeting on October 28, 2024. A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.
01 Other Events
Item 8.01 Other Events. On October 28, 2024, the Company announced that in the multiple injection cohort of the Company's ongoing phase 1b clinical trial of CAN-3110 in rHGG, investigators observed ongoing improved survival compared to historical controls, with 3 out of 6 patients with rHGG still alive more than one year (12.2, 13.0, and 18.7 months, respectively) after initiation of experimental treatment with repeated CAN-3110 injections. The data also showed discrepancies between imaging and histologic findings, suggesting radiologic pseudo-progression: there was a near absence of tumor cells alongside dense lymphocyte infiltrates in biopsies obtained after CAN-3110 administration, especially in patients with enhancement on post-treatment MRI scans.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated October 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: October 28, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer